 Shelley Miyamoto
Concepts (372)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 34 | 2023 | 670 | 3.880 |
Why?
| | Heart Defects, Congenital | 14 | 2023 | 683 | 2.780 |
Why?
| | Heart Ventricles | 15 | 2022 | 723 | 2.500 |
Why?
| | Cardiomyopathy, Dilated | 13 | 2021 | 350 | 2.440 |
Why?
| | MicroRNAs | 8 | 2023 | 600 | 1.920 |
Why?
| | Heart Failure | 16 | 2023 | 1958 | 1.910 |
Why?
| | Cardiomyopathies | 7 | 2023 | 298 | 1.680 |
Why?
| | Circulating MicroRNA | 3 | 2023 | 24 | 1.660 |
Why?
| | Myocardium | 8 | 2021 | 911 | 1.530 |
Why?
| | Hypoplastic Left Heart Syndrome | 6 | 2017 | 114 | 1.420 |
Why?
| | Milrinone | 2 | 2021 | 24 | 1.250 |
Why?
| | Myocytes, Cardiac | 7 | 2021 | 449 | 1.250 |
Why?
| | Ventricular Remodeling | 4 | 2021 | 224 | 1.230 |
Why?
| | Ventricular Function, Right | 2 | 2018 | 256 | 1.020 |
Why?
| | Cardiomyopathy, Hypertrophic | 3 | 2023 | 121 | 1.010 |
Why?
| | Heart Diseases | 5 | 2023 | 329 | 0.970 |
Why?
| | Child | 58 | 2023 | 18400 | 0.970 |
Why?
| | Graft Rejection | 8 | 2021 | 511 | 0.910 |
Why?
| | Infant | 32 | 2022 | 7943 | 0.770 |
Why?
| | Ventricular Function, Left | 5 | 2018 | 477 | 0.770 |
Why?
| | Graft Survival | 7 | 2023 | 443 | 0.750 |
Why?
| | Child, Preschool | 36 | 2021 | 9114 | 0.700 |
Why?
| | Receptors, Adrenergic, beta | 3 | 2016 | 126 | 0.660 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 76 | 0.660 |
Why?
| | Phosphodiesterase 3 Inhibitors | 2 | 2016 | 13 | 0.640 |
Why?
| | Fever | 1 | 2020 | 280 | 0.630 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 22 | 0.620 |
Why?
| | Down-Regulation | 3 | 2021 | 594 | 0.610 |
Why?
| | Steroids | 2 | 2015 | 143 | 0.560 |
Why?
| | Hemodynamics | 6 | 2015 | 1015 | 0.560 |
Why?
| | Humans | 80 | 2023 | 114043 | 0.540 |
Why?
| | Female | 60 | 2023 | 59325 | 0.540 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2017 | 141 | 0.540 |
Why?
| | Male | 55 | 2023 | 55396 | 0.530 |
Why?
| | Fontan Procedure | 4 | 2023 | 168 | 0.510 |
Why?
| | Histone Deacetylases | 1 | 2017 | 194 | 0.500 |
Why?
| | Biomarkers | 9 | 2021 | 3397 | 0.470 |
Why?
| | Echocardiography | 6 | 2021 | 569 | 0.460 |
Why?
| | Case-Control Studies | 8 | 2021 | 3003 | 0.450 |
Why?
| | Cardiovascular Diseases | 2 | 2022 | 1726 | 0.420 |
Why?
| | Adaptation, Physiological | 2 | 2017 | 484 | 0.420 |
Why?
| | Waiting Lists | 2 | 2013 | 206 | 0.410 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 39 | 0.400 |
Why?
| | Animals, Newborn | 5 | 2021 | 777 | 0.390 |
Why?
| | Recovery of Function | 2 | 2015 | 573 | 0.380 |
Why?
| | Calcium-Binding Proteins | 3 | 2021 | 205 | 0.380 |
Why?
| | Phosphoric Diester Hydrolases | 3 | 2016 | 44 | 0.380 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 3 | 2017 | 24 | 0.380 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2321 | 0.370 |
Why?
| | Dexmedetomidine | 3 | 2017 | 45 | 0.370 |
Why?
| | Adolescent | 32 | 2023 | 17800 | 0.370 |
Why?
| | Phenotype | 4 | 2023 | 2784 | 0.360 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2010 | 241 | 0.340 |
Why?
| | Age Factors | 9 | 2018 | 2885 | 0.340 |
Why?
| | Prospective Studies | 11 | 2021 | 6195 | 0.320 |
Why?
| | Primary Graft Dysfunction | 1 | 2009 | 29 | 0.320 |
Why?
| | Rats, Sprague-Dawley | 5 | 2021 | 2182 | 0.320 |
Why?
| | Cardiolipins | 3 | 2021 | 70 | 0.320 |
Why?
| | Adenosine Monophosphate | 2 | 2021 | 49 | 0.310 |
Why?
| | Reoviridae Infections | 1 | 2009 | 52 | 0.310 |
Why?
| | Granuloma, Plasma Cell | 1 | 2008 | 12 | 0.300 |
Why?
| | Signal Transduction | 3 | 2017 | 4501 | 0.300 |
Why?
| | Retrospective Studies | 21 | 2021 | 12521 | 0.300 |
Why?
| | Myocarditis | 1 | 2009 | 93 | 0.290 |
Why?
| | Kidney Transplantation | 2 | 2023 | 538 | 0.290 |
Why?
| | Cardiac Catheterization | 4 | 2017 | 545 | 0.280 |
Why?
| | Databases, Factual | 5 | 2016 | 1125 | 0.280 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2017 | 314 | 0.280 |
Why?
| | Ventricular Outflow Obstruction | 2 | 2022 | 38 | 0.270 |
Why?
| | Phosphorylation | 4 | 2021 | 1558 | 0.270 |
Why?
| | Calcium | 3 | 2021 | 1089 | 0.260 |
Why?
| | Immunosuppressive Agents | 4 | 2023 | 641 | 0.260 |
Why?
| | Infant, Newborn | 10 | 2021 | 5038 | 0.260 |
Why?
| | Coronary Artery Disease | 3 | 2018 | 611 | 0.250 |
Why?
| | Treatment Outcome | 14 | 2021 | 9049 | 0.240 |
Why?
| | Adenylyl Cyclases | 2 | 2016 | 83 | 0.240 |
Why?
| | Fibrosis | 2 | 2017 | 452 | 0.240 |
Why?
| | Coronary Vessels | 2 | 2017 | 234 | 0.240 |
Why?
| | Heart-Assist Devices | 4 | 2019 | 500 | 0.230 |
Why?
| | Cardiomyopathy, Restrictive | 1 | 2023 | 9 | 0.220 |
Why?
| | Pulmonary Artery | 1 | 2009 | 1024 | 0.210 |
Why?
| | Heart | 3 | 2022 | 613 | 0.210 |
Why?
| | Sarcomeres | 1 | 2023 | 90 | 0.210 |
Why?
| | Data Accuracy | 1 | 2022 | 48 | 0.200 |
Why?
| | Transcriptome | 2 | 2021 | 724 | 0.200 |
Why?
| | Cyclic AMP | 2 | 2014 | 225 | 0.200 |
Why?
| | Fibroma | 1 | 2022 | 21 | 0.200 |
Why?
| | Heart Neoplasms | 1 | 2022 | 49 | 0.200 |
Why?
| | Barth Syndrome | 1 | 2021 | 8 | 0.200 |
Why?
| | Electron Transport Complex I | 1 | 2021 | 33 | 0.190 |
Why?
| | Longevity | 1 | 2022 | 137 | 0.190 |
Why?
| | Cardiopulmonary Bypass | 3 | 2022 | 174 | 0.190 |
Why?
| | Focal Adhesions | 1 | 2021 | 42 | 0.190 |
Why?
| | Cytokines | 1 | 2009 | 1824 | 0.190 |
Why?
| | Fetofetal Transfusion | 1 | 2021 | 21 | 0.190 |
Why?
| | Amniotic Fluid | 1 | 2021 | 64 | 0.180 |
Why?
| | Heart Rate | 3 | 2023 | 710 | 0.180 |
Why?
| | Cells, Cultured | 4 | 2019 | 3861 | 0.180 |
Why?
| | Calcium Channel Agonists | 1 | 2020 | 10 | 0.180 |
Why?
| | Probenecid | 1 | 2020 | 7 | 0.180 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 64 | 0.180 |
Why?
| | Young Adult | 12 | 2023 | 10444 | 0.180 |
Why?
| | Serum | 2 | 2018 | 57 | 0.180 |
Why?
| | Hypertension, Pulmonary | 3 | 2017 | 1736 | 0.180 |
Why?
| | Isoproterenol | 2 | 2018 | 105 | 0.180 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 121 | 0.170 |
Why?
| | Apoptosis | 1 | 2009 | 2349 | 0.170 |
Why?
| | ROC Curve | 3 | 2017 | 441 | 0.170 |
Why?
| | Tissue Donors | 3 | 2016 | 314 | 0.160 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2020 | 122 | 0.160 |
Why?
| | Atrial Function, Right | 1 | 2019 | 12 | 0.160 |
Why?
| | Troponin I | 1 | 2019 | 68 | 0.160 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2021 | 38 | 0.160 |
Why?
| | Fatty Acids | 1 | 2021 | 380 | 0.160 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 228 | 0.160 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2016 | 82 | 0.160 |
Why?
| | Mitochondria, Heart | 2 | 2020 | 72 | 0.150 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 489 | 0.150 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 36 | 0.150 |
Why?
| | Heart Atria | 1 | 2019 | 107 | 0.150 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2013 | 371 | 0.150 |
Why?
| | Extracellular Matrix | 1 | 2021 | 436 | 0.150 |
Why?
| | Surgical Wound Dehiscence | 1 | 2017 | 19 | 0.150 |
Why?
| | Time Factors | 6 | 2018 | 6077 | 0.150 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 486 | 0.150 |
Why?
| | Animals | 10 | 2021 | 31565 | 0.140 |
Why?
| | Protein Kinase C beta | 1 | 2017 | 24 | 0.140 |
Why?
| | Patient Transfer | 1 | 2019 | 142 | 0.140 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2017 | 14 | 0.140 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 160 | 0.140 |
Why?
| | Survival Analysis | 4 | 2021 | 1206 | 0.140 |
Why?
| | Adult | 12 | 2023 | 30375 | 0.140 |
Why?
| | Research Design | 1 | 2022 | 919 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 813 | 0.140 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2016 | 16 | 0.140 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2016 | 11 | 0.140 |
Why?
| | Electrocardiography | 3 | 2015 | 561 | 0.140 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 714 | 0.140 |
Why?
| | Galectin 3 | 1 | 2016 | 18 | 0.140 |
Why?
| | Specimen Handling | 1 | 2018 | 153 | 0.140 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 56 | 0.140 |
Why?
| | Transition to Adult Care | 1 | 2017 | 60 | 0.140 |
Why?
| | Perioperative Care | 1 | 2017 | 126 | 0.130 |
Why?
| | Genetic Markers | 1 | 2017 | 320 | 0.130 |
Why?
| | Sirolimus | 1 | 2017 | 181 | 0.130 |
Why?
| | Mutation | 3 | 2023 | 3338 | 0.130 |
Why?
| | Vectorcardiography | 1 | 2016 | 5 | 0.130 |
Why?
| | Self Care | 1 | 2019 | 350 | 0.130 |
Why?
| | Isoenzymes | 1 | 2017 | 283 | 0.130 |
Why?
| | Plasma | 1 | 2018 | 181 | 0.130 |
Why?
| | Risk Factors | 9 | 2018 | 8614 | 0.130 |
Why?
| | Arrhythmias, Cardiac | 1 | 2018 | 282 | 0.130 |
Why?
| | Vascular Resistance | 1 | 2017 | 340 | 0.130 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 270 | 0.130 |
Why?
| | Vasoconstriction | 1 | 2017 | 177 | 0.130 |
Why?
| | Exosomes | 1 | 2017 | 92 | 0.130 |
Why?
| | Statistics as Topic | 1 | 2016 | 291 | 0.130 |
Why?
| | Up-Regulation | 1 | 2018 | 802 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 496 | 0.120 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 246 | 0.120 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 79 | 0.120 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2015 | 64 | 0.120 |
Why?
| | Exercise Test | 3 | 2023 | 547 | 0.120 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 153 | 0.120 |
Why?
| | Rats | 4 | 2021 | 4913 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 2015 | 133 | 0.120 |
Why?
| | Ketamine | 1 | 2015 | 92 | 0.120 |
Why?
| | Stroke Volume | 2 | 2016 | 513 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1519 | 0.120 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 153 | 0.120 |
Why?
| | Prognosis | 4 | 2015 | 3315 | 0.110 |
Why?
| | Hypoalbuminemia | 1 | 2014 | 27 | 0.110 |
Why?
| | Organ Transplantation | 1 | 2016 | 159 | 0.110 |
Why?
| | Propensity Score | 1 | 2015 | 225 | 0.110 |
Why?
| | Patient Compliance | 1 | 2017 | 524 | 0.110 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 1 | 2013 | 9 | 0.110 |
Why?
| | Growth Disorders | 1 | 2014 | 77 | 0.110 |
Why?
| | Coronary Angiography | 1 | 2016 | 308 | 0.110 |
Why?
| | Anthracyclines | 1 | 2013 | 42 | 0.110 |
Why?
| | Fetal Heart | 1 | 2013 | 37 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2017 | 666 | 0.110 |
Why?
| | Tissue and Organ Procurement | 1 | 2016 | 226 | 0.110 |
Why?
| | Vascular Diseases | 1 | 2016 | 233 | 0.110 |
Why?
| | Myosin Heavy Chains | 1 | 2014 | 178 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 42 | 0.100 |
Why?
| | Connexin 43 | 1 | 2012 | 23 | 0.100 |
Why?
| | Interleukin-1 | 1 | 2016 | 965 | 0.100 |
Why?
| | Heart Arrest | 1 | 2015 | 293 | 0.100 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 156 | 0.100 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 94 | 0.100 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 170 | 0.100 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4392 | 0.100 |
Why?
| | Altitude | 2 | 2021 | 435 | 0.090 |
Why?
| | American Heart Association | 2 | 2023 | 264 | 0.090 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2014 | 221 | 0.090 |
Why?
| | Incidence | 2 | 2015 | 2314 | 0.090 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 154 | 0.090 |
Why?
| | Pulmonary Embolism | 1 | 2012 | 180 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2010 | 63 | 0.090 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 231 | 0.090 |
Why?
| | RNA | 1 | 2016 | 807 | 0.090 |
Why?
| | Lymphoproliferative Disorders | 1 | 2010 | 46 | 0.090 |
Why?
| | Disease Management | 1 | 2014 | 556 | 0.090 |
Why?
| | Mycoses | 1 | 2010 | 66 | 0.090 |
Why?
| | Patient Selection | 1 | 2014 | 629 | 0.090 |
Why?
| | Colorado | 6 | 2017 | 4090 | 0.080 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1310 | 0.080 |
Why?
| | Cohort Studies | 6 | 2015 | 4883 | 0.080 |
Why?
| | Cardiac Surgical Procedures | 2 | 2017 | 414 | 0.080 |
Why?
| | Air Ambulances | 1 | 2010 | 34 | 0.080 |
Why?
| | Transplantation Conditioning | 1 | 2010 | 149 | 0.080 |
Why?
| | Oxygen Consumption | 2 | 2023 | 587 | 0.080 |
Why?
| | Transplantation, Homologous | 3 | 2021 | 377 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1168 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 61 | 0.080 |
Why?
| | Travel | 1 | 2010 | 121 | 0.080 |
Why?
| | Registries | 2 | 2014 | 1764 | 0.080 |
Why?
| | Mitral Valve Stenosis | 1 | 2008 | 22 | 0.080 |
Why?
| | Cytomegalovirus Infections | 1 | 2010 | 180 | 0.080 |
Why?
| | United States | 7 | 2022 | 12137 | 0.080 |
Why?
| | Angioplasty, Balloon | 1 | 2009 | 89 | 0.070 |
Why?
| | Reoperation | 3 | 2021 | 513 | 0.070 |
Why?
| | RNA, Messenger | 3 | 2021 | 2550 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1381 | 0.070 |
Why?
| | RNA, Transfer, Glu | 1 | 2007 | 5 | 0.070 |
Why?
| | Pregnancy | 2 | 2021 | 5499 | 0.070 |
Why?
| | Oxidation-Reduction | 2 | 2021 | 917 | 0.070 |
Why?
| | Mitochondrial Diseases | 1 | 2007 | 76 | 0.070 |
Why?
| | Stem Cells | 1 | 2010 | 541 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2009 | 297 | 0.070 |
Why?
| | Myocardial Contraction | 2 | 2019 | 318 | 0.060 |
Why?
| | Stents | 1 | 2009 | 466 | 0.060 |
Why?
| | Stroke | 1 | 2012 | 1019 | 0.060 |
Why?
| | Middle Aged | 4 | 2016 | 26605 | 0.060 |
Why?
| | Pilot Projects | 2 | 2019 | 1360 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2017 | 990 | 0.050 |
Why?
| | Risk | 2 | 2019 | 810 | 0.050 |
Why?
| | Blotting, Western | 2 | 2016 | 1143 | 0.050 |
Why?
| | Palliative Care | 1 | 2009 | 641 | 0.050 |
Why?
| | Everolimus | 1 | 2023 | 61 | 0.050 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2537 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2023 | 76 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2015 | 742 | 0.050 |
Why?
| | Tacrolimus | 1 | 2023 | 134 | 0.050 |
Why?
| | Endopeptidase K | 1 | 2021 | 14 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2023 | 212 | 0.050 |
Why?
| | Acyltransferases | 1 | 2021 | 46 | 0.050 |
Why?
| | Ribonucleases | 1 | 2021 | 52 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1690 | 0.050 |
Why?
| | Light Coagulation | 1 | 2021 | 7 | 0.050 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2022 | 68 | 0.050 |
Why?
| | Genotype | 2 | 2017 | 1757 | 0.050 |
Why?
| | Fetoscopy | 1 | 2021 | 28 | 0.050 |
Why?
| | Serum Response Factor | 1 | 2021 | 29 | 0.050 |
Why?
| | Microscopy, Atomic Force | 1 | 2021 | 113 | 0.050 |
Why?
| | Drainage | 1 | 2021 | 145 | 0.040 |
Why?
| | Gene Expression | 2 | 2017 | 1417 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 605 | 0.040 |
Why?
| | Postoperative Complications | 3 | 2021 | 2122 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1422 | 0.040 |
Why?
| | TRPV Cation Channels | 1 | 2020 | 30 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 949 | 0.040 |
Why?
| | Neoplasms | 1 | 2013 | 2086 | 0.040 |
Why?
| | Recurrence | 2 | 2012 | 925 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 452 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2021 | 237 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2023 | 351 | 0.040 |
Why?
| | Resource Allocation | 1 | 2019 | 37 | 0.040 |
Why?
| | Inflammation | 1 | 2009 | 2464 | 0.040 |
Why?
| | Risk Assessment | 3 | 2016 | 2958 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2017 | 1880 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 590 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 388 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 388 | 0.040 |
Why?
| | Ventricular Function | 1 | 2019 | 57 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 182 | 0.040 |
Why?
| | Flecainide | 1 | 2018 | 7 | 0.040 |
Why?
| | Treatment Failure | 2 | 2010 | 330 | 0.040 |
Why?
| | Guinea Pigs | 1 | 2018 | 136 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 725 | 0.040 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 2018 | 59 | 0.040 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2018 | 106 | 0.040 |
Why?
| | Freezing | 1 | 2018 | 84 | 0.040 |
Why?
| | Adenoidectomy | 1 | 2017 | 60 | 0.040 |
Why?
| | Kidney | 1 | 2023 | 1182 | 0.030 |
Why?
| | Cell Size | 1 | 2017 | 79 | 0.030 |
Why?
| | Atrial Natriuretic Factor | 1 | 2016 | 56 | 0.030 |
Why?
| | Homeostasis | 1 | 2020 | 570 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 3498 | 0.030 |
Why?
| | Observer Variation | 1 | 2017 | 298 | 0.030 |
Why?
| | Sampling Studies | 1 | 2016 | 92 | 0.030 |
Why?
| | Renin-Angiotensin System | 1 | 2017 | 72 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 735 | 0.030 |
Why?
| | Tonsillectomy | 1 | 2017 | 72 | 0.030 |
Why?
| | Mitochondria | 1 | 2021 | 744 | 0.030 |
Why?
| | Brain Death | 1 | 2016 | 30 | 0.030 |
Why?
| | Hot Temperature | 1 | 2018 | 301 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2017 | 148 | 0.030 |
Why?
| | Sympathetic Nervous System | 1 | 2017 | 171 | 0.030 |
Why?
| | Autopsy | 1 | 2016 | 83 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2629 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 126 | 0.030 |
Why?
| | Diastole | 1 | 2016 | 137 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2019 | 694 | 0.030 |
Why?
| | Systole | 1 | 2016 | 176 | 0.030 |
Why?
| | Action Potentials | 1 | 2018 | 406 | 0.030 |
Why?
| | Italy | 1 | 2015 | 92 | 0.030 |
Why?
| | Cardiac Output | 1 | 2015 | 143 | 0.030 |
Why?
| | Markov Chains | 1 | 2015 | 114 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 433 | 0.030 |
Why?
| | DNA, Complementary | 1 | 2015 | 255 | 0.030 |
Why?
| | Reference Values | 1 | 2016 | 739 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2017 | 206 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2015 | 99 | 0.030 |
Why?
| | Exons | 1 | 2015 | 301 | 0.030 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2017 | 182 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 768 | 0.030 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 29 | 0.030 |
Why?
| | Analgesics | 1 | 2015 | 156 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1310 | 0.030 |
Why?
| | Drug Therapy | 1 | 2014 | 74 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 695 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2016 | 1218 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 951 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 820 | 0.030 |
Why?
| | Mice | 3 | 2015 | 14841 | 0.030 |
Why?
| | Exercise | 1 | 2023 | 1642 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2013 | 110 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2014 | 136 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 213 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 787 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1331 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2013 | 249 | 0.020 |
Why?
| | Pediatrics | 1 | 2019 | 982 | 0.020 |
Why?
| | Heart Function Tests | 1 | 2012 | 60 | 0.020 |
Why?
| | Nutritional Status | 1 | 2014 | 286 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 1791 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2384 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1078 | 0.020 |
Why?
| | Mass Screening | 1 | 2017 | 979 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2010 | 242 | 0.020 |
Why?
| | France | 1 | 2010 | 28 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 278 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 52 | 0.020 |
Why?
| | Body Weight | 1 | 2014 | 868 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1638 | 0.020 |
Why?
| | Shock, Cardiogenic | 1 | 2010 | 55 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 266 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2010 | 237 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 492 | 0.020 |
Why?
| | Adaptive Immunity | 1 | 2010 | 154 | 0.020 |
Why?
| | Internationality | 1 | 2010 | 143 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1836 | 0.020 |
Why?
| | Tricuspid Atresia | 1 | 2008 | 6 | 0.020 |
Why?
| | Venae Cavae | 1 | 2008 | 9 | 0.020 |
Why?
| | Vena Cava, Superior | 1 | 2008 | 23 | 0.020 |
Why?
| | Device Removal | 1 | 2009 | 123 | 0.020 |
Why?
| | Anticoagulants | 1 | 2012 | 547 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1024 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 444 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2008 | 135 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 2764 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1144 | 0.020 |
Why?
| | Probability | 1 | 2008 | 286 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 362 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2007 | 281 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2008 | 407 | 0.020 |
Why?
| | Aged | 2 | 2014 | 18969 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4595 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2008 | 1117 | 0.020 |
Why?
| | Length of Stay | 1 | 2008 | 957 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2010 | 1735 | 0.010 |
Why?
|
|
Miyamoto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|